BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 37289449)

  • 1. Comparing Risk for Second Primary Cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for Prostate Cancer, 2002-2015.
    Pithadia KJ; Advani PG; Citrin DE; Bekelman JE; Withrow DR; Berrington de Gonzalez A; Morton LM; Schonfeld SJ
    JAMA Oncol; 2023 Aug; 9(8):1119-1123. PubMed ID: 37289449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second cancer risk after primary cancer treatment with three-dimensional conformal, intensity-modulated, or proton beam radiation therapy.
    Xiang M; Chang DT; Pollom EL
    Cancer; 2020 Aug; 126(15):3560-3568. PubMed ID: 32426866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer.
    Sheets NC; Goldin GH; Meyer AM; Wu Y; Chang Y; Stürmer T; Holmes JA; Reeve BB; Godley PA; Carpenter WR; Chen RC
    JAMA; 2012 Apr; 307(15):1611-20. PubMed ID: 22511689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer.
    Bekelman JE; Mitra N; Efstathiou J; Liao K; Sunderland R; Yeboa DN; Armstrong K
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e325-34. PubMed ID: 21498008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial.
    Viani GA; Viana BS; Martin JE; Rossi BT; Zuliani G; Stefano EJ
    Cancer; 2016 Jul; 122(13):2004-11. PubMed ID: 27028170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance.
    Sveistrup J; af Rosenschöld PM; Deasy JO; Oh JH; Pommer T; Petersen PM; Engelholm SA
    Radiat Oncol; 2014 Feb; 9():44. PubMed ID: 24495815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of clinical outcomes between three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer.
    Shimizuguchi T; Nihei K; Okano T; Machitori Y; Ito K; Karasawa K
    Int J Clin Oncol; 2017 Apr; 22(2):373-379. PubMed ID: 27778117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer.
    Lin SH; Zhang N; Godby J; Wang J; Marsh GD; Liao Z; Komaki R; Ho L; Hofstetter WL; Swisher SG; Mehran RJ; Buchholz TA; Elting LS; Giordano SH
    Cancer; 2016 Mar; 122(6):917-28. PubMed ID: 26716915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation.
    Hummel S; Simpson EL; Hemingway P; Stevenson MD; Rees A
    Health Technol Assess; 2010 Oct; 14(47):1-108, iii-iv. PubMed ID: 21029717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in Postoperative Intensity-Modulated Radiation Therapy Use and Its Association With Survival Among Patients With Incompletely Resected Non-Small Cell Lung Cancer.
    Yu B; Jun Ma S; Waldman O; Dunne-Jaffe C; Chatterjee U; Turecki L; Gill J; Yendamuri K; Iovoli A; Farrugia M; Singh AK
    JAMA Netw Open; 2022 Sep; 5(9):e2230704. PubMed ID: 36074462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
    Li X; Kitpanit S; Lee A; Mah D; Sine K; Sherman EJ; Dunn LA; Michel LS; Fetten J; Zakeri K; Yu Y; Chen L; Kang JJ; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Lee NY
    JAMA Netw Open; 2021 Jun; 4(6):e2113205. PubMed ID: 34143193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer.
    Pinkawa M; Piroth MD; Holy R; Djukic V; Klotz J; Krenkel B; Eble MJ
    Strahlenther Onkol; 2011 Aug; 187(8):479-84. PubMed ID: 21789739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Cardiovascular Toxicity According to Tumor Laterality Among Older Patients With Early Stage Non-small Cell Lung Cancer Treated With Radiation Therapy.
    Liu BY; Rehmani S; Kale MS; Marshall D; Rosenzweig KE; Kong CY; Wisnivesky J; Sigel K
    Chest; 2022 Jun; 161(6):1666-1674. PubMed ID: 35063448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of intensity-modulated radiotherapy and conventional conformal radiotherapy in the treatment of prostate cancer after radical prostatectomy.
    Goldin GH; Sheets NC; Meyer AM; Kuo TM; Wu Y; Stürmer T; Godley PA; Carpenter WR; Chen RC
    JAMA Intern Med; 2013 Jun; 173(12):1136-43. PubMed ID: 23689844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensity-Modulated Radiation Therapy May Improve Local-Regional Tumor Control for Locally Advanced Non-Small Cell Lung Cancer Compared With Three-Dimensional Conformal Radiation Therapy.
    Wang J; Zhou Z; Liang J; Feng Q; Xiao Z; Hui Z; Wang X; Lv J; Chen D; Zhang H; Ji Z; Cao J; Liu L; Jiang W; Men Y; Xu C; Dai J; Yin W; Wang L
    Oncologist; 2016 Dec; 21(12):1530-1537. PubMed ID: 27628491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for stage I-II natural killer/T-cell lymphoma nasal type: dosimetric and clinical results.
    Shen Q; Ma X; Hu W; Chen L; Huang J; Guo Y
    Radiat Oncol; 2013 Jun; 8():152. PubMed ID: 23800149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer.
    Zapatero A; Roch M; Büchser D; Castro P; Fernández-Banda L; Pozo G; Liñán O; Martin de Vidales C; Cruz-Conde A; García-Vicente F
    Clin Transl Oncol; 2017 Sep; 19(9):1161-1167. PubMed ID: 28374321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity.
    Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
    Radiat Oncol; 2017 Aug; 12(1):131. PubMed ID: 28810885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity and cost-effectiveness analysis of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for postoperative treatment of gynecologic cancers.
    Chen LA; Kim J; Boucher K; Terakedis B; Williams B; Nickman NA; Gaffney DK
    Gynecol Oncol; 2015 Mar; 136(3):521-8. PubMed ID: 25562668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of intensity modulated radiation therapy to 3-dimensional conformal radiation in locally advanced lung cancer: pathological and clinical outcomes.
    Appel S; Bar J; Ben-Nun A; Perelman M; Alezra D; Urban D; Ben-Ayun M; Honig N; Ofek E; Katzman T; Onn A; Chatterji S; Dubinski S; Tsvang L; Felder S; Kraitman J; Haisraely O; Rabin Alezra T; Lieberman S; Marom EM; Golan N; Simansky D; Symon Z; Lawrence YR
    Br J Radiol; 2019 May; 92(1097):20180960. PubMed ID: 30864828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.